EUVIMEDEUVIMED entdecken
Crossref

Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently

Zhaoqi Chen, Yan Liu, Nianci Chen, Haiyan Xing, Zheng Tian, Kejing Tang, Qing Rao, Yingxi Xu, Ying Wang, Min Wang, Jianxiang Wang

Science China Life Sciences · 2023-04 · 66 (4) · 754-770

DOI: 10.1007/s11427-022-2173-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science China Life Sciences, online erschienen am 14.10.2022. Verfasst von Zhaoqi Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD19 chimeric antigen receptor (CAR) T cells have shown robust efficacy in relapsed and refractory acute lymphoblastic leukemia (R/R ALL), but compromising result in chronic lymphoblastic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). CD19 relapse and the lack of CAR-T cell persistence which result in treatment failure are considerable obstacles to overcome. CAR-T targeting CD20 is an option for salvaging CD19 CAR-T failure. Previous studies have established variant structures of bispecific CAR-T which could avoid antigen-loss and immune escape. Here, we constructed tandem and loop CAR structures targeting both CD19 and CD20 antigen. Bispecific CAR-T cells could eliminate either CD19 or CD20 negative lymphoma cells, suggesting they exhibited dual antigen targeting of CD19 and CD20. By comparing the efficiency of four bispecific CAR modified T cells, it was found that loop2019 CAR was the best structure among them to eradicate lymphoma cell lines and patients' primary lymphoma or CLL cells in a very low dose in vitro and prolong the survival time dramatically in lymphoma xenograft mice model. These data highlighted the potential of loop2019 CAR-T in clinical treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenLeukemia, Lymphocytic, Chronic, B-CellLymphomaHumansMiceAnimalsT-LymphocytesAntigens, CD20Antigens, CD19Immunotherapy, Adoptive

Stichwörter der Autor:innen

CD19CD20CLLbispecific targetingchimeric antigen receptorlymphoma

Substanzen

Receptors, Chimeric AntigenAntigens, CD20Antigens, CD19

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
  • Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
  • Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
  • National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
  • State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China. wangjxm@ihcams.ac.cn.
  • Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China. wangjxm@ihcams.ac.cn.

Zitieren

APA

Chen, Z., Liu, Y., Chen, N., Xing, H., Tian, Z., Tang, K., Rao, Q., Xu, Y., Wang, Y., Wang, M., & Wang, J. (2023). Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently. Science China Life Sciences, 66(4), 754-770. https://doi.org/10.1007/s11427-022-2173-9

Vancouver

Chen Z, Liu Y, Chen N, Xing H, Tian Z, Tang K, et al. Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently. Science China Life Sciences. 2023;66(4):754-770. doi:10.1007/s11427-022-2173-9

BibTeX
@article{Chen2023,
  author = {Chen, Zhaoqi and Liu, Yan and Chen, Nianci and Xing, Haiyan and Tian, Zheng and Tang, Kejing and Rao, Qing and Xu, Yingxi and Wang, Ying and Wang, Min and Wang, Jianxiang},
  title = {Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently},
  journal = {Science China Life Sciences},
  year = {2023},
  volume = {66},
  number = {4},
  pages = {754--770},
  doi = {10.1007/s11427-022-2173-9}
}
Kostenlos starten →